arrow
G

Gaetano Giuffrida

azienda ospedaliero universitaria policlinico g.rodolico-san marco
H指数:15
被引数:1,049

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Physical Activity, Bleeding Incidence and Health-Related Quality of Life, in Patients With Haemophilia A Without Inhibitors, Treated With Emicizumab: A Post-Hoc Descriptive Analysis of the Power Study Data

活动、出血发生率及与健康相关的生活质量,在未使用抑制剂的血友病A患者中使用依库珠单抗治疗:POWER研究数据的回顾性描述分析

2026-09-160
OAAI
The impact of caplacizumab in the treatment of immune thrombotic thrombocytopenic purpura. A retrospective monocentric cohort study

卡普拉珠单抗在治疗免疫性血栓性血小板减少性紫癜中的影响。一项回顾性单中心队列研究

2026-05-150
OAAI
Incidence of infections in patients treated with rituximab for autoimmune disorders of hematological Interest or non-Hodgkin lymphoma

利妥昔单抗治疗血液学相关自身免疫性疾病或非霍奇金淋巴瘤患者的感染发生率

2026-05-090
OAAI
Integrating Clinical, Functional, and Patient-Reported Outcomes in Haemophilia Care: A Delphi-Based Consensus on a New Monitoring Tool

整合临床、功能及患者报告结局在血友病护理中的应用:基于德尔菲法的关于新监测工具的共识

2026-04-060
OAAI
Vitamin K Antagonists (VKAs) and Novel Oral Anticoagulants (NOACs) Safety Comparison Based on Data from EudraVigilance Database

基于EudraVigilance数据库的维生素K拮抗剂(VKAs)和新口服抗凝剂(NOACs)安全性比较

2025-10-180
OA
Real-World Data on Effectiveness and Safety of First-Line Use of Caplacizumab in Italian Centers for the Treatment of Thrombotic Thrombocytopenic Purpura: The Roscapli Study
2024-10-310
OAAI
Acid sphingomyelinase deficiency (ASMD): addressing knowledge gaps in unmet needs and patient journey in Italy-a Delphi consensus
2023-03-075
PRE
Real-World Clinical Outcomes and Replacement Factor VIII Consumption in Patients with Haemophilia A in Italy: A Comparison between Prophylaxis Pre and Post Octocog Alfa (BAY 81-8973)
2022-06-152
OAAI
Second-line administration of thrombopoietin receptor agonists in immune thrombocytopenia: Italian Delphi-based consensus recommendations
2021-10-0912
OAAI